Key result
Allele-selective siRNA suppresses on-target mutant huntingtin mRNA by ~74% with minimal off-target effects.
Why the study?
Does SNP-targeted siRNA selectively suppress mutant huntingtin in primary ex vivo myeloid cells from Huntington's disease patients?
Does SNP-targeted siRNA selectively suppress mutant huntingtin in primary ex vivo myeloid cells from Huntington's disease patients?
Absolute Event Rate: 74% vs 17%
p-value: p=<0.05
Allele-selective suppression of mutant huntingtin using SNP-targeted siRNA is highly SNP-dependent in primary human blood cells, with implications for clinical trial target selection.
May inform SNP selection for siRNA therapies in Huntington's disease; leaves open translation from ex vivo cells to clinical use.
Post-transcriptional gene silencing is a promising therapy for the monogenic, autosomal dominant, Huntington's disease (HD). However, wild-type huntingtin (HTT) has important cellular functions, so the ideal strategy would selectively lower mutant HTT while sparing wild-type. HD patients were genotyped for heterozygosity at three SNP sites, before phasing each SNP allele to wild-type or mutant HTT. Primary ex vivo myeloid cells were isolated from heterozygous patients and transfected with SNP-targeted siRNA, using glucan particles taken up by phagocytosis. Highly selective mRNA knockdown was achieved when targeting each allele of rs362331 in exon 50 of the HTT transcript; this selectivity was also present on protein studies. However, similar selectivity was not observed when targeting rs362273 or rs362307. Furthermore, HD myeloid cells are hyper-reactive compared to control. Allele-selective suppression of either wild-type or mutant HTT produced a significant, equivalent reduction in the cytokine response of HD myeloid cells to LPS, suggesting that wild-type HTT has a novel immune function. We demonstrate a sequential therapeutic process comprising genotyping and mutant HTT-linkage of SNPs, followed by personalised allele-selective suppression in a small patient cohort. We further show that allele-selectivity in ex vivo patient cells is highly SNP-dependent, with implications for clinical trial target selection.
No takes yet. Share an insight, caveat, or question.
Miller et al. (2017) studied Huntington's disease. Allele-selective siRNA targeted to rs362331 vs. Nonsense siRNA and off-target allele was evaluated on Allele-specific mRNA suppression (p=<0.05). Allele-selective siRNA targeting the rs362331 SNP in primary human Huntington's disease myeloid cells achieved 74% on-target mutant huntingtin mRNA suppression with only 17% off-target suppression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: